NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27062820 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yu-Hsun Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Drug Resistance, Neoplasm, Ovarian Neoplasms, Neoplastic Stem Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hualien Tzu Chi Hospital.
Abstract (Originalsprache)
Advanced-stage ovarian cancer remains a major clinical challenge because of its aggressive behavior and the frequent development of chemoresistance. The nuclear factor erythroid-derived 2–like 2 (NRF2) signaling pathway regulates cellular redox homeostasis. However, its role in ovarian cancer stem-like cells remains unclear. Therefore, we aimed to investigate the effects of NRF2 overexpression on acetaldehyde dehydrogenase (ALDH)+ KURAMOCHI ovarian cancer cells in vitro and in vivo. In particular, we investigated the effects of NRF2 on tumor-associated behaviors, chemoresistance, and signaling pathways. Lentivirus-mediated NRF2 overexpression activated extracellular signal-regulated kinase and AKT signaling. Moreover, it modulated tumor-associated phenotypes, including proliferation, migration, and invasion. NRF2-overexpressing cells exhibited significantly enhanced migratory and invasive capacities, increased resistance to paclitaxel and carboplatin, and reduced apoptosis. Furthermore, the expression of anti-apoptotic proteins was upregulated, and caspase-3 activation was attenuated. In xenograft models, NRF2 overexpression promoted tumor growth and increased the expression of antioxidant and angiogenic factors, including heme oxygenase-1 and vascular endothelial growth factor A. Collectively, these findings demonstrate that NRF2 regulates ovarian cancer aggressiveness and chemoresistance by coordinating stress response signaling, survival pathways, and tumor progression. Therefore, targeting NRF2-mediated signaling represents a promising therapeutic strategy for overcoming drug resistance and improving outcomes in patients with ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.
- Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.
- Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.
- Institute of Medical Sciences, Tzu Chi University, Hualien 970, Taiwan.
Förderung
- Hualien Tzu Chi Hospital
Zitieren
APA
Chang, Y. H., Wang, K. H., & Ding, D. C. (2026). NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062820
Vancouver
Chang YH, Wang KH, Ding DC. NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062820
BibTeX
@article{Chang2026,
author = {Chang, Yu-Hsun and Wang, Kai-Hung and Ding, Dah-Ching},
title = {NRF2 Drives Aggressiveness and Chemoresistance in Ovarian Cancer Stem-like Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27062820}
}
EUVIMED